000			01690 a2200373 4500
005			20250516152529.0
264		0	_c20151103
008			201511s 0 0 eng d
022			_a1548-8756
024	7		_a10.14694/EdBook_AM.2013.33.e280 _2doi
040			_aNLM _beng _cNLM
100	1		_aChow, Laura Q M
245	0	0	_aExploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer. _h[electronic resource]
260			_bAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting _c2013
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review; Video-Audio Media
650	0	4	_aAnimals
650	0	4	_aAntibodies _xadverse effects
650	0	4	_aAntineoplastic Agents _xadverse effects
650	0	4	_aApoptosis _xdrug effects
650	0	4	_aB7-H1 Antigen _xantagonists & inhibitors
650	0	4	_aCTLA-4 Antigen _xantagonists & inhibitors
650	0	4	_aCarcinoma, Non-Small-Cell Lung _xdrug therapy
650	0	4	_aHumans
650	0	4	_aImmunotherapy _xadverse effects
650	0	4	_aLung Neoplasms _xdrug therapy
650	0	4	_aLymphocyte Activation _xdrug effects
650	0	4	_aMolecular Targeted Therapy _xadverse effects
650	0	4	_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors
650	0	4	_aRisk Factors
650	0	4	_aSignal Transduction _xdrug effects
650	0	4	_aTreatment Outcome
773	0		_tAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
856	4	0	_uhttps://doi.org/10.14694/EdBook_AM.2013.33.e280 _zAvailable from publisher's website
999			_c22787063 _d22787063